Collegium Pharmaceutical Inc (COLL.OQ)

About

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	--
Market Cap(Mil.):	$348.59
Shares Outstanding(Mil.):	29.57
Dividend:	--
Yield (%):	--

Financials

	COLL.OQ	Industry	Sector
P/E (TTM):	--	30.95	32.74
EPS (TTM):	-3.65	--	--
ROI:	-99.46	14.84	14.38
ROE:	-101.15	16.34	16.07

Latest News about COLL.OQ

BRIEF-Collegium Appoints Shirley Kuhlmann As General Counsel

* COLLEGIUM ANNOUNCES THE APPOINTMENT OF SHIRLEY KUHLMANN AS GENERAL COUNSEL Source text for Eikon: Further company coverage:

19 Mar 2018

BRIEF-Collegium Reports Q4 Loss Per Share $0.54

* COLLEGIUM REPORTS FOURTH QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

07 Mar 2018

BRIEF-Collegium To Host Conference Call To Discuss Fourth Quarter 2017 Financial Results And Provide Corporate Update

* COLLEGIUM TO HOST CONFERENCE CALL TO DISCUSS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

26 Feb 2018

BRIEF-Collegium Filed Patent Infringement Lawsuit Against Teva Pharma USA

* COLLEGIUM PHARMA SAYS FILED PATENT INFRINGEMENT LAWSUIT IN U.S. DISTRICT COURT FOR DISTRICT OF DELAWARE AGAINST TEVA PHARMACEUTICALS USA INC

22 Feb 2018

BRIEF-Janus Henderson Group Reports 10.1 Pct Passive Stake In Collegium Pharmaceutical

* JANUS HENDERSON GROUP PLC REPORTS 10.1 PERCENT PASSIVE STAKE IN COLLEGIUM PHARMACEUTICAL AS OF DEC 31, 2017 - SEC FILING Source text : [http://bit.ly/2mvIp5l] Further company coverage:

11 Jan 2018

BRIEF-Depomed Announces Closing Of Nucynta Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES CLOSING OF NUCYNTA COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

10 Jan 2018

BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical

* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL

14 Dec 2017

BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical

* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL

04 Dec 2017

BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise

* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE